drugset / Trial / NCT05949632

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

NCT05949632

Phase 1/2 Terminated 5 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.

Timeline

Start
2024-04-16
Primary completion
2025-06-06
Completion
2025-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB099280 Unknown
Background Axitinib Small molecule

Indications